DrugPatentWatch Database Preview
Tripoint Company Profile
» See Plans and Pricing
What is the competitive landscape for TRIPOINT, and when can generic versions of TRIPOINT drugs launch?
TRIPOINT has one approved drug.
There are five US patents protecting TRIPOINT drugs.
There are twenty-three patent family members on TRIPOINT drugs in eighteen countries and two supplementary protection certificates in two countries.
Summary for Tripoint
| International Patents: | 23 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Tripoint
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | RX | Yes | No | 8,425,938 | Get Started for $10 | Y | Get Started for $10 | |||
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | RX | Yes | No | 8,470,367 | Get Started for $10 | Y | Get Started for $10 | |||
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | RX | Yes | No | 8,163,306 | Get Started for $10 | Y | Get Started for $10 | |||
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | RX | Yes | No | 8,431,156 | Get Started for $10 | Y | Get Started for $10 | |||
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-002 | Dec 20, 2018 | RX | Yes | Yes | 8,470,367 | Get Started for $10 | Y | Get Started for $10 | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Tripoint Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2004283565 | Get Started for $10 |
| Japan | 2007505894 | Get Started for $10 |
| European Patent Office | 1909770 | Get Started for $10 |
| African Regional IP Organization (ARIPO) | 200603602 | Get Started for $10 |
| Denmark | 1663175 | Get Started for $10 |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tripoint Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0162036 | 2000C/032 | Belgium | Get Started for $10 | PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329 |
| 0162036 | C300028 | Netherlands | Get Started for $10 | PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
